S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
S&P 500   3,977.26 (+0.16%)
DOW   32,444.02 (+0.64%)
QQQ   308.34 (-0.82%)
AAPL   158.41 (-1.15%)
MSFT   276.58 (-1.42%)
META   202.52 (-1.69%)
GOOGL   102.51 (-2.78%)
AMZN   97.33 (-0.82%)
TSLA   191.33 (+0.48%)
NVDA   265.75 (-0.76%)
NIO   8.94 (-1.43%)
BABA   85.74 (-1.33%)
AMD   96.16 (-1.83%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.96 (-1.96%)
CGC   1.89 (-0.79%)
GE   93.23 (+2.04%)
DIS   95.10 (+1.08%)
AMC   4.39 (-1.79%)
PFE   40.31 (-0.20%)
PYPL   73.61 (-0.37%)
NFLX   326.69 (-0.52%)
NASDAQ:HROW

Harrow Health - HROW Stock Forecast, Price & News

$20.80
+2.38 (+12.92%)
(As of 03/27/2023 01:04 PM ET)
Add
Compare
Today's Range
$18.75
▼
$20.80
50-Day Range
$13.93
▼
$19.24
52-Week Range
$5.40
▼
$20.80
Volume
455,733 shs
Average Volume
342,120 shs
Market Capitalization
$563.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.00

Harrow Health MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
13.5% Upside
$23.00 Price Target
Short Interest
Bearish
7.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Harrow Health in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
485.71%
From $0.14 to $0.82 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

782nd out of 995 stocks

Pharmaceutical Preparations Industry

383rd out of 482 stocks

See Top Rated MarketRank™ Stocks Here

HROW stock logo

About Harrow Health (NASDAQ:HROW) Stock

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Stock News Headlines

March 24, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and NeuroPace (NPCE)
March 24, 2023 | markets.businessinsider.com
B.Riley Financial Sticks to Its Buy Rating for Harrow Health (HROW)
March 27, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 24, 2023 | finance.yahoo.com
Q4 2022 Harrow Health Inc Earnings Call
March 23, 2023 | finance.yahoo.com
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
March 22, 2023 | americanbankingnews.com
Harrow Health (HROW) Scheduled to Post Earnings on Thursday
March 17, 2023 | benzinga.com
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
March 14, 2023 | benzinga.com
ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
March 27, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
March 13, 2023 | benzinga.com
Harrow Health Shareholder Notice
March 13, 2023 | finance.yahoo.com
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%
March 6, 2023 | benzinga.com
ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM
March 6, 2023 | finance.yahoo.com
Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance
March 2, 2023 | finance.yahoo.com
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
March 1, 2023 | morningstar.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 27, 2023 | benzinga.com
Harrow Health, Inc.: Company Investigated by the Portnoy Law Firm
February 25, 2023 | seekingalpha.com
Buy Harrow Health: Correcting A Shortsighted View
February 25, 2023 | benzinga.com
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 25, 2023 | benzinga.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM
February 24, 2023 | benzinga.com
Harrow Health Investor Alert
February 24, 2023 | seekingalpha.com
Harrow Health Has Done Very Well For Us In The Past Few Months, And We Expect More
February 24, 2023 | benzinga.com
The Law Offices of Frank R. Cruz Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 23, 2023 | benzinga.com
Harrow Health Shareholder Action Reminder
February 23, 2023 | technews.tmcnet.com
The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors
February 22, 2023 | msn.com
Harrow Health drops on new short report from Bonitas Research (update)
February 16, 2023 | finance.yahoo.com
Is Harrow Health (HROW) an Undervalued Stock?
February 15, 2023 | finance.yahoo.com
Harrow Launches Next-Generation Compounded Atropine Formulations
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

HROW Company Calendar

Last Earnings
11/09/2021
Today
3/27/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HROW
CUSIP
N/A
CIK
1360214
Web
www.harrowinc.com
Phone
(615) 733-4730
Fax
858-345-1745
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+14.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
143.64
P/E Growth
N/A
Net Income
$-18,010,000.00
Net Margins
-15.90%
Pretax Margin
-25.27%
Return on Equity
28.87%
Return on Assets
1.57%

Debt

Debt-to-Equity Ratio
83.80
Current Ratio
3.49
Quick Ratio
3.20

Sales & Book Value

Annual Sales
$88.60 million
Price / Sales
6.14
Cash Flow
$0.07 per share
Price / Cash Flow
292.26
Book Value
$0.41 per share
Price / Book
49.05

Miscellaneous

Outstanding Shares
27,070,000
Free Float
23,213,000
Market Cap
$544.38 million
Optionable
Optionable
Beta
0.17

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HROW Stock - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares.
View HROW analyst ratings or view top-rated stocks.

What is Harrow Health's stock price forecast for 2023?

1 brokers have issued 12-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $24.00. On average, they predict the company's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price.
View analysts price targets for HROW or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2023?

Harrow Health's stock was trading at $14.76 at the beginning of 2023. Since then, HROW shares have increased by 36.2% and is now trading at $20.11.
View the best growth stocks for 2023 here.

Are investors shorting Harrow Health?

Harrow Health saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,160,000 shares, an increase of 32.5% from the February 28th total of 1,630,000 shares. Based on an average trading volume of 347,600 shares, the short-interest ratio is currently 6.2 days.
View Harrow Health's Short Interest.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our HROW earnings forecast.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.34. The company had revenue of $18.71 million for the quarter, compared to analyst estimates of $17.27 million. Harrow Health had a positive trailing twelve-month return on equity of 28.87% and a negative net margin of 15.90%. During the same period in the prior year, the business posted $0.32 earnings per share.

What ETFs hold Harrow Health's stock?

ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS), Hartford Multifactor Small Cap ETF (ROSC) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB),

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health updated its FY 2023 earnings guidance on Monday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $117.72 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

What is Harrow Health's stock symbol?

Harrow Health trades on the NASDAQ under the ticker symbol "HROW."

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (13.95%), Renaissance Technologies LLC (4.18%), Portolan Capital Management LLC (3.59%), Geode Capital Management LLC (0.90%), Acuitas Investments LLC (0.88%) and EAM Investors LLC (0.86%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harrow Health's stock price today?

One share of HROW stock can currently be purchased for approximately $20.11.

How much money does Harrow Health make?

Harrow Health (NASDAQ:HROW) has a market capitalization of $544.38 million and generates $88.60 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Harrow Health have?

The company employs 182 workers across the globe.

How can I contact Harrow Health?

Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745.

This page (NASDAQ:HROW) was last updated on 3/27/2023 by MarketBeat.com Staff